Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Botulinum Toxin Type A for Postoperative Scar Prevention
NCT06349733Phase 1Completed
- Sponsor
- Qilu Hospital of Shandong University
- Start
- Mar 2023
- Primary completion
- Oct 2023
- Modality
- Recombinant Proteins and Enzymes
- Countries
- 1
01
Overview
Phase 1, randomised, double-blind trial of botulinum toxin type A in surgical scar (4 arms), sponsored by Qilu Hospital of Shandong University. Primary endpoint: Modified Stony Brook Scar Evaluation Scale at 6 months. Started Mar 2023; status: completed.
02
Drugs
botulinum toxin type A
03
Conditions
surgical scar
Beyond the preview
Go deeper on NCT06349733.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06349733.